

Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning

Marina V. Basalay^{1,2†}, Svetlana Mastitskaya^{1†}, Aleksander Mrochek², Gareth L. Ackland^{1,3}, Ana Gutierrez del Arroyo³, Jenifer Sanchez³, Per-Ove Sjoquist⁴, John Pernow⁴, Alexander V. Gourine^{1*}, and Andrey Gourine^{4*}

¹Centre for Cardiovascular and Metabolic Neuroscience, Neuroscience, Physiology & Pharmacology, University College London, Gower Street, London WC1E 6BT, UK; ²Research Centre Cardiology, Luxembourg Street 110, Minsk 220026, Belarus; ³William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK; and ⁴Karolinska Institute, Division of Cardiology, Karolinska University Hospital, Solna 171 76, Stockholm, Sweden

Received 29 June 2016; revised 21 August 2016; accepted 23 September 2016; online publish-ahead-of-print 4 October 2016

Time for primary review: 2 days

Aims

Although the nature of the humoral factor which mediates cardioprotection established by remote ischaemic conditioning (Rlc) remains unknown, parasympathetic (vagal) mechanisms appear to play a critical role. As the production and release of many gut hormones is modulated by the vagus nerve, here we tested the hypothesis that Rlc cardioprotection is mediated by the actions of glucagon-like peptide-1 (GLP-1).

Methods and results

A rat model of myocardial infarction (coronary artery occlusion followed by reperfusion) was used. Remote ischaemic pre- (RIPre) or perconditioning (RIPer) was induced by 15 min occlusion of femoral arteries applied prior to or during the myocardial ischaemia. The degree of RIPre and RIPer cardioprotection was determined in conditions of cervical or subdiaphragmatic vagotomy, or following blockade of GLP-1 receptors (GLP-1R) using specific antagonist Exendin(9–39). Phosphorylation of PI3K/AKT and STAT3 was assessed. RIPre and RIPer reduced infarct size by ~50%. In conditions of bilateral cervical or subdiaphragmatic vagotomy RIPer failed to establish cardioprotection. GLP-1R blockade abolished cardioprotection induced by either RIPre or RIPer. Exendin(9–39) also prevented RIPre-induced AKT phosphorylation. Cardioprotection induced by GLP-1R agonist Exendin-4 was preserved following cervical vagotomy, but was abolished in conditions of M3 muscarinic receptor blockade.

Conclusions

These data strongly suggest that GLP-1 functions as a humoral factor of remote ischaemic conditioning cardioprotection. This phenomenon requires intact vagal innervation of the visceral organs and recruitment of GLP-1R-mediated signalling. Cardioprotection induced by GLP-1R activation is mediated by a mechanism involving M3 muscarinic receptors.

Keywords

Cardioprotection • Glucagon-like peptide-1 • Myocardial infarction • Myocardial ischaemia • Parasympathetic • Remote ischaemic conditioning • Reperfusion • Vagus nerve

1. Introduction

Powerful innate mechanisms of cardioprotection can be recruited by remote ischaemic conditioning (Rlc), which can be established by cycles of ischaemia/reperfusion applied to an organ/tissue distant from the heart. In several animal models significant reduction of myocardial

ischaemia/reperfusion injury was demonstrated when Rlc stimulus was applied either before (remote ischaemic preconditioning, RIPre) or during myocardial ischaemia (remote ischaemic perconditioning, RIPer),^{1,2} or after the onset of reperfusion (remote ischaemic postconditioning).³ Clinical trials have demonstrated the efficacy of Rlc in reducing infarct size in patients with an acute myocardial infarction (AMI),^{4,5} in reducing

* Corresponding authors. Tel/fax: +442076796480, E-mail: a.gourine@ucl.ac.uk; Tel/fax: +37517369840, E-mail: agourine@hotmail.com

† The first two authors contributed equally to this work.

A.V.G. and A.G. are joint last authors.

© The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

myocardial damage during cardiac surgery⁶ and improving long term prognosis in both patient cohorts.^{6,7} Although the exact mechanisms underlying Rlc cardioprotection are not fully understood, a number of studies suggested the involvement of both humoral^{8–11} and neural signalling pathways.^{1,12–14} Several candidate humoral factors of Rlc have been proposed, including stromal cell-derived factor-1 α ,¹⁵ nitrite/nitric oxide,¹⁶ interleukin-10,¹⁷ microRNA-144,¹⁸ apolipoprotein A-I¹⁹ and alpha-ketoglutarate-dependent dioxygenase EglN1.²⁰ However, the full extent of Rlc cardioprotection cannot be explained by the actions of any of these factors alone.

There is strong evidence that parasympathetic (vagal) mechanisms are critically important for RIPre cardioprotection. RIPre was reported to be abolished by selective genetic inhibition of brainstem vagal preganglionic neurones,¹³ muscarinic receptor blockade,^{13,14} bilateral cervical vagotomy³ or sectioning of the posterior gastric branch of the vagus nerve.²¹ Electrical stimulation of the whole vagus nerve at the cervical level^{22,23} or isolated posterior gastric branch of the vagus²¹ establishes cardioprotection. These data suggest that visceral organs, innervated by the posterior gastric branch of the vagus nerve, are the likely source of a humoral factor (or factors) of Rlc cardioprotection. Glucagon-like peptide-1 (GLP-1) is the most notable of all humoral factors, which originate from the visceral organs and known to have cardioprotective properties. GLP-1 is an incretin hormone released by the L-cells of the intestine in response to the ingestion of food.^{24,25} Release of GLP-1 is modulated by vagal efferent (motor) activity^{26,27} and there is also evidence that GLP-1 may interact with vagal sensory fibres innervating the viscera.²⁶ GLP-1 actions appear to be mediated via glucagon-like peptide-1 receptor (GLP-1R)-dependent and independent mechanisms,^{28,29} although the existence of the latter is debated. Studies conducted in animal models demonstrated potent cardioprotection by GLP-1R activation.³⁰ The efficacy of GLP-1R agonists in reducing infarct size was also shown in human studies.^{31,32} Recent study conducted in patients with type 2 diabetes demonstrated significant reduction in frequency of adverse cardiovascular events and death from cardiovascular causes by treatment with GLP-1 analogue liraglutide.³³ The molecular weight of GLP-1 is ~ 3.3 kDa and it appears to satisfy the key criteria of the humoral preconditioning factor (including molecular weight of less than 8 kDa), suggested by Lang and colleagues on the basis of the proteomic analysis of blood samples obtained from experimental animals receiving the RIPre stimulus.³⁴

This study was designed to test the hypothesis that cardioprotection established by Rlc is mediated by the actions of GLP-1. Taken into the account that the parasympathetic nervous system appears to be critically important for RIPre cardioprotection, we also investigated the significance of vagal mechanisms in establishing cardioprotection induced by the GLP-1R agonist Exendin-4 (Ex4).

2. Methods

All the experiments were performed in accordance with the European Commission Directive 2010/63/EU (European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes) and the UK Home Office (Scientific Procedures) Act (1986) with project approval from the respective Institutional Animal Care and Use Committees.

2.1 Animal preparation

Adult male Sprague Dawley rats (280–320 g) were anaesthetized with pentobarbital sodium (induction 60 mg kg⁻¹ i.p.; maintenance 15 mg

kg⁻¹ h⁻¹ i.v.). Adequate anaesthesia was ensured by maintaining stable levels of the arterial blood pressure and heart rate and confirmed by the absence of a withdrawal response to a paw pinch. The right carotid artery and left jugular vein were cannulated for the measurement of the arterial blood pressure and administration of anaesthetic or test compounds, respectively. The trachea was cannulated to allow mechanical ventilation with room air using a positive pressure rodent ventilator (tidal volume ~ 8 –10 ml kg⁻¹; frequency ~ 60 strokes min⁻¹). Partial pressures of O₂ and CO₂ as well as pH of the arterial blood were measured regularly. A standard lead II ECG was recorded. The body temperature was maintained at 37.0 \pm 0.5 °C with a servo-controlled heating blanket.

2.2 Model of myocardial infarction

An established rat model of myocardial ischaemia/reperfusion injury was used.^{3,13,21} The heart was exposed via a left thoracotomy and a 5–0 monofilament polypropylene suture was passed around the left anterior descending coronary (LAD) artery to induce a temporary occlusion. LAD artery was occluded for 30 min followed by reperfusion lasting 120 min.

2.3 Infarct size measurement

At the end of the reperfusion period, the LAD artery was ligated, and 5% Evans Blue dye solution (0.2 ml) was infused via the jugular vein to determine the area at risk. The animal was then given an anaesthetic overdose (pentobarbital, 200 mg kg⁻¹, i.v.), the heart was excised, the left ventricle (LV) was isolated, frozen, and sectioned into 5–6 transverse slices from the apex to the base. The area at risk was demarcated by the absence of Evans Blue staining. LV slices were then incubated with 1% 2,3,5-triphenyltetrazolium chloride (TTC) in Tris buffer (pH 7.4) for 15 min at 37 °C and fixed in 4% formalin for 24 h. Viable myocardium is stained red by TTC, whereas necrotic myocardium appears white. The area at risk and the necrotic area were determined by computerized planimetry, normalized to the weight of each slice, with the degree of necrosis (i.e. infarct size) expressed as the percentage of area at risk, as described.^{3,13,21}

2.4 Immunoblotting

For the analysis of protein phosphorylation, Western blot was performed on the myocardium from the area at risk. The ventricular tissue was excised, frozen in liquid nitrogen and stored at -80 °C before the assays. Total phosphatidylinositol 3-kinase AKT (PI3K/AKT), phospho-AKT (Ser473), janus-activated kinase (JAK) signal transducer and activator of transcription (STAT3) and phospho-STAT3 (Tyr705) were immunodetected in cell lysates (whole cell fractions) using specific primary antibodies (all from Cell Signalling Technology, UK). Proteins were electrophoretically separated in SDS-PAGE gels and transferred to polyvinylidene difluoride membranes (Amersham Biosciences, USA) according to the manufacturer's instructions. After antibody labelling, detection was performed (ECL detection system, Amersham Biosciences, USA). Densitometry was used to calculate the ratio of phosphorylated and total protein normalized to the expression of β -actin (Santa Cruz UK) to control protein loading.

2.5 Experimental protocols

2.5.1 Experiment 1. The effect of vagotomy on RlPer cardioprotection

There is evidence that RlPre cardioprotection is abolished in conditions of either cervical³ or subdiaphragmatic²¹ vagotomy. However, the role of parasympathetic mechanisms in mediating RlPer cardioprotection




Figure 1 Cardioprotection induced by remote ischaemic preconditioning requires intact parasympathetic innervation of visceral organs. (A) Illustration of the experimental protocols. In all the protocols, the rat model of myocardial infarction involved 30 min of left anterior descending coronary artery occlusion followed by 120 min of reperfusion. Arrows indicate time (15 min before myocardial ischaemia) of bilateral cervical (cerv.) or subdiaphragmatic (subd.) vagotomy. Remote ischaemic preconditioning (RlPer) was induced by occlusion of both femoral arteries for 15 min starting 10 min after the onset of myocardial ischaemia. (B) Infarct size is presented as a percentage of the area at risk. Individual data and means \pm SD are shown. ** $P < 0.01$; *** $P < 0.001$.

remains unknown. RlPer was induced by occlusion of both femoral arteries for 15 min starting 10 min after the onset of myocardial ischaemia (see timeline *Figure 1A*). For bilateral cervical vagotomy, both nerves were exposed at the neck level and sectioned 15 min prior to myocardial ischaemia. To perform total subdiaphragmatic vagotomy, minimal incision was made to gain access to the abdominal cavity, the left lobes of the liver were gently pulled aside, the stomach was retracted caudally to expose the oesophagus, the vagal trunks were carefully dissected under the diaphragm and sectioned.^{21,35}

2.5.2 Experiment 2. The effect of GLP-1 receptor blockade on Rlc-induced cardioprotection and phosphorylation of AKT and STAT3

Rlc was induced by 15 min occlusion of both femoral arteries, followed by reperfusion, starting either 25 min prior or 10 min after the onset of myocardial ischaemia (see timeline *Figure 2A*). GLP-1R antagonist Exendin(9–39) (Ex(9–39), 50 $\mu\text{g kg}^{-1}$, i.v.),^{36,37} was administered 40 min or 15 min before the onset of ischaemia in animals receiving the RlPre or RlPer stimulus, respectively. The effect of Ex(9–39) on cardioprotection established by classical myocardial ischaemic preconditioning (lPre) was also determined. lPre was induced by three episodes of myocardial ischaemia (LAD occlusion; 3 + 5 + 5 min) separated by 5-min periods of reperfusion. Ex(9–39) was given 15 min before the first ischaemic episode. The dose of Ex(9–39) was selected on the basis of previously published reports.³⁸ In a separate experiment the effect of Ex(9–39) on RlPre-induced phosphorylation of AKT and STAT3 in the myocardium was assessed. The hearts were collected 15 min after the onset of myocardial reperfusion.

2.5.3 Experiment 3. The effect of vagotomy and systemic muscarinic receptor blockade on cardioprotection established by GLP-1 receptor activation

Intravenous administration of GLP-1R agonist Exendin-4 (Ex4) in doses ranging between 1–10 $\mu\text{g kg}^{-1}$ has been shown to protect the rat heart against myocardial ischaemia/reperfusion injury.³⁹ In this study we used Ex4 in 5 $\mu\text{g kg}^{-1}$ dose to determine the efficacy of GLP-1R activation in establishing cardioprotection in conditions of bilateral cervical vagotomy, systemic muscarinic receptor blockade (atropine methyl nitrate; initial bolus dose 2 mg kg^{-1} , i.v., followed by infusion at a rate of 1 $\text{mg kg}^{-1} \text{h}^{-1}$) or M3 muscarinic receptor blockade (4-DAMP; 2 mg kg^{-1} , i.v.). Experimental protocols are illustrated on *Figure 3A*.

2.5.4 Experiment 4. The effect of Rlc on plasma level of GLP-1

After 12-h overnight fast, the animals were anaesthetized and instrumented as described above. Rlc was induced by 15 min occlusion of both femoral arteries, followed by reperfusion. Samples of the arterial blood (300 μl) were collected into pre-chilled EDTA-Eppendorf tubes at 4 time points: 10 min prior to and 5, 20, and 30 min after the onset of limb ischaemia or sham-Rlc. Dipeptidyl peptidase-4 (DPP-4) inhibitor (50 μM ; EMD Millipore) was added to the collected samples and plasma was separated by centrifugation (10 min; 1000g; 4°C). Total GLP-1 in plasma was measured using MesoScale Discovery Total GLP-1 (v2) kit (Rockville, USA).




Figure 2 GLP-1 receptors mediate remote ischaemic conditioning cardioprotection. (A) Illustration of the experimental protocols. Myocardial ischaemic preconditioning (IPre) was induced by three episodes of myocardial ischaemia (3 + 5 + 5 min) separated by 5-min periods of reperfusion. Remote ischaemic preconditioning (RIPre) was induced by occlusion of both femoral arteries for 15 min starting 25 min before the onset of myocardial ischaemia. Arrows indicate the time (15 min before IPre, RIPre or myocardial ischaemia) of intravenous administration of GLP-1 receptor antagonist Exendin(9–39) (Ex(9–39)). (B) Infarct size is presented as a percentage of the area at risk. Individual data and means ± SD are shown. ***P* < 0.01; ****P* < 0.001. (C) Left: representative immunoblots showing total AKT and phospho-AKT (Ser473) protein expression in left ventricular lysates at 15 min of myocardial reperfusion in rats subjected to preparative sham surgery (sham-RIPre), application of RIPre stimulus, or application of RIPre stimulus in conditions of systemic GLP-1R blockade with Ex(9–39). Right: summary data illustrating means ± SD of the densitometry of phospho-AKT-to-AKT ratio. **P* < 0.05. (D) Left: representative immunoblots showing total STAT3 and phospho-STAT3 (Tyr705) protein expression in left ventricular lysates at 15 min of myocardial reperfusion in rats subjected to preparative sham surgery (sham-RIPre), application of RIPre stimulus, or application of RIPre stimulus in conditions of systemic GLP-1R blockade with Ex(9–39). Right: summary data illustrating means ± SD of the densitometry of phospho-STAT3-to-STAT3 ratio.

2.6 Statistical analysis

One-way ANOVA (Tukey's and Bonferroni's Multiple Comparison Tests) was used for statistical analysis of the data. Values of *P* < 0.05 were considered to be significant.

3. Results

In the *Experiment 1*, an increase in heart rate was observed in animals subjected to RIPer in conditions of subdiaphragmatic vagotomy during

myocardial ischaemia and reperfusion period (Supplementary material online, *Table*). In the *Experiment 3*, mean arterial blood pressure increased in Ex4-treated animals subjected to cervical vagotomy before myocardial ischaemia. Heart rate increased before myocardial ischaemia and remained elevated during myocardial ischaemia and during reperfusion (Supplementary material online, *Table*). No other differences in mean arterial blood pressure and heart rate during ischaemia and reperfusion were observed between the experimental groups of animals (Supplementary material online, *Table*). Areas at risk were similar between all the experimental groups (data not shown). *Figures 1B, 2B,*




Figure 3 Cardioprotection induced by GLP-1 receptor activation is mediated by a muscarinic mechanism. (A) Illustration of the experimental protocols. Downward arrows indicate time (15 min before myocardial ischaemia) of intravenous administration of GLP-1 receptor agonist Exendin-4 (Ex4). Upward arrows indicate time (30 min before myocardial ischaemia) of cervical vagotomy, start of atropine infusion or administration of M3 muscarinic receptor antagonist 4DAMP. (B) Infarct size is presented as a percentage of the area at risk. Individual data and means \pm SD are shown. ** $P < 0.01$; *** $P < 0.001$.

and 3B illustrate infarct sizes expressed as percentages of the areas at risk.

3.1 Experiment 1. The effect of vagotomy on RlPer cardioprotection

Average infarct size in animals subjected to 30 min of LAD occlusion followed by 120 min of reperfusion was $56 \pm 10\%$ (Figure 1B). RlPer significantly reduced myocardial ischaemia/reperfusion injury (infarct size $27 \pm 6\%$, $P < 0.001$), but failed to establish cardioprotection in conditions of either bilateral cervical or subdiaphragmatic vagotomy (Figure

1B). Vagotomy per se had no effect on myocardial ischaemia/reperfusion injury (Figure 1B).

3.2 Experiment 2. The effect of GLP-1 receptor blockade on Rlc-induced cardioprotection and phosphorylation of AKT and STAT3

To determine whether GLP-1 may act as a humoral factor of Rlc we next determined the efficacy of IPre, RlPre, and RlPer in establishing cardioprotection in conditions of systemic GLP-1R blockade (Figure 2B). Systemic administration of a specific GLP-1R antagonist Ex(9–39) blocked cardioprotection induced by RlPre and RlPer (infarct sizes $48 \pm 10\%$ and $52 \pm 9\%$, respectively), but had no effect on cardioprotection conferred by classical direct myocardial IPre (infarct size $24 \pm 4\%$) (Figure 2B). RlPre-induced AKT phosphorylation was blocked ($P < 0.05$) by systemic treatment with Ex(9–39) (Figure 2C). RlPre had no significant effect on STAT3 phosphorylation (Figure 2D).

3.3 Experiment 3. The effect of vagotomy and systemic muscarinic receptor blockade on cardioprotection established by GLP-1 receptor activation

We next determined whether GLP-1R activation induces cardioprotection via recruitment of vagal mechanisms. Intravenous infusion of GLP-1R agonist Ex4 significantly reduced (by 40%, $P < 0.01$) the extent of myocardial ischaemia/reperfusion injury (Figure 3B). Ex4-induced cardioprotection was not affected by bilateral cervical vagotomy (infarct size $27 \pm 11\%$, NS vs. Ex4 treatment) (Figure 3B). However, systemic muscarinic receptor blockade (atropine) abolished Ex4-induced cardioprotection (infarct size $52 \pm 9\%$, $P < 0.01$ vs. Ex4). Ex4 also failed to establish cardioprotection in conditions of systemic M3 receptor blockade with 4-DAMP (infarct size $57 \pm 6\%$, $P < 0.001$ vs. Ex4) (Figure 3B).

3.4 Experiment 4. The effect of Rlc on plasma level of GLP-1

Moderate increases in the level of circulating (arterial) GLP-1 compared to the baseline values were observed 30 min after the onset of limbs ischaemia (15 min into the limb reperfusion period) (4.7 ± 0.9 vs. 3.0 ± 0.7 pg/ml at baseline; $P < 0.05$; Table 1). Arterial GLP-1 levels were not affected by sham-Rlc procedure (Table 1).

4. Discussion

To the best of our knowledge, this is the first experimental study which demonstrated that a particular humoral factor is *causally* involved in cardioprotection induced by remote ischaemic conditioning. Recent study identified the likely origin of the cardioprotective humoral factor which appears to be produced by the visceral organs innervated by the posterior gastric branch of the vagus nerve.²¹ Organs of the gastrointestinal tract indeed represent a major source of many factors with known cardioprotective properties, including GLP-1. Here we show that the remote conditioning-induced cardioprotection and phosphorylation of pro-survival kinase AKT are abolished by systemic GLP-1R blockade with Ex(9–39). Ex(9–39) has been used in many published studies, including several seminal reports, which described physiological role and significance of GLP-1R-mediated signalling,⁴⁰ and off-target (i.e. not on GLP-

Table 1 The effect of remote ischaemic conditioning (Rlc) or sham-Rlc on plasma level of glucagon-like peptide-1 (in pg ml⁻¹)

	n	Time from the onset of limb ischaemia or sham (min)			
		-10	5	20	30
Sham	8	4.1 ± 0.7	5.2 ± 1.0	4.4 ± 0.9	5.1 ± 1.1
Rlc	8	3.0 ± 0.7	3.1 ± 0.6	3.4 ± 0.6	4.7 ± 0.9*

*Significant difference from the baseline value ($P < 0.05$).

1R) effects of this peptide antagonist have never been observed. The data obtained also suggest that pathways of cardioprotection downstream of GLP-1R activation are independent of vagal activity but involve recruitment of M3 receptor-dependent mechanism. These results are in agreement with the data reported recently, showing that in isolated hearts cardioprotection established by plasma dialysate collected from rats receiving the Rlc stimulus is abolished by muscarinic receptor blockade.⁴¹

4.2 Vagus nerve and remote ischaemic conditioning cardioprotection

Since the importance of vagal mechanisms in mediating cardioprotection induced by Rlc was first proposed,⁴² results of several experimental studies provided strong evidence in support of the idea that the intact parasympathetic mechanisms are essential for Rlc cardioprotection. RIPre cardioprotection was found to be abolished by selective genetic targeting and silencing of vagal preganglionic neurones, bilateral cervical vagotomy or systemic muscarinic receptor blockade.^{3,13,14} Anatomical and functional cholinergic innervation of the cardiac ventricles was demonstrated in a number of studies (for recent experimental reports see Refs^{43,44}) and it was suggested that RIPre is mediated by the actions of acetylcholine released from vagal efferent fibres which innervate the LV myocardium.¹³ However, the mechanism involving vagally-mediated reflexes cannot fully explain how RIPre is able to protect the transplanted or denervated hearts, or cross species transfer of Rlc cardioprotection by plasma dialysate.⁸⁻¹¹ Taken together, the available data suggest that production and release of a humoral factor of Rlc cardioprotection is under parasympathetic control. In support of this idea, it was recently demonstrated that RIPre fails to establish cardioprotection in conditions of selective sectioning of the posterior gastric branch of the vagus nerve,²¹ pointing to the likely source of the cardioprotective humoral factor. Results of the present study show that RIPer cardioprotection also requires intact parasympathetic innervation of visceral organs. Therefore, the common vagal mechanisms appear to mediate cardioprotection established by Rlc applied either before or during myocardial ischaemia and require GLP-1R-mediated signalling.

4.3 Humoral factor(s) of Rlc cardioprotection. The role of GLP-1R-mediated signalling

A significant number of studies demonstrated successful transfer of humoral factor responsible for Rlc cardioprotection with plasma or dialysate, obtained after Rlc, to another animal or isolated hearts, even across species (see for example Refs^{8,10,11,41}) The molecular weight of this humoral factor of cardioprotection appears to be less than 8 kDa,³⁴

and several candidate molecules have been proposed.¹⁵⁻¹⁹ Cell-derived factor-1 α ,¹⁵ nitrite/nitric oxide,¹⁶ interleukin-10,¹⁷ microRNA-144¹⁸ were shown to be involved in cardioprotection; however, Rlc cardioprotection cannot be fully explained by any of the identified factors acting alone. In addition, SDF-1 α has been proposed to act as a circulating mediator of Rlc.¹⁵ However, treatment with a selective inhibitor of SDF-1 α only partially attenuated but did not block Rlc cardioprotection,¹⁵ suggesting the existence of other (parallel) mechanisms. Proteome/sequencing analysis also failed to reveal the nature of this factor.^{34,45,46} One recent study reported Rlc-induced changes in plasma levels of seven proteins.⁴⁶ These factors are involved in the control of haemostasis, lipid transport, iron regulation and inflammation. Some of the identified proteins (when applied exogenously) could mimic Rlc in experimental models; however, it remains unknown whether blockade of their actions has an effect on Rlc cardioprotection.

GLP-1 can activate GLP-1R expressed by visceral vagal afferents acting in a paracrine manner, but also has endocrine functions.^{24,25} Originally identified to be expressed by pancreatic β -cells, GLP-1R is now known to be widely distributed in many tissues, including the atrial myocardium, coronary vessels, and possibly, ventricles.⁴⁷ Several studies demonstrated high efficacy of GLP-1R agonists in reducing the infarct size.³⁰ However, the mechanisms by which GLP-1R activation protects the ischaemic myocardium remain largely unknown. Both GLP-1R-dependent and GLP-1R-independent mechanisms have been proposed.^{28,29} As the majority of the intestinally derived GLP-1 is degraded by the DPP-4, low levels of circulating GLP-1 are usually reported.²⁴ Due to high rate of enzymatic degradation and renal clearance, GLP-1 has a short half-life (1-2 min) in plasma which represents a major limitation for its detection.^{24,48} In this study, we observed moderate increases in plasma GLP-1 level 30 min after the onset of the Rlc stimulus, probably due to high variability of GLP-1 plasma concentration and short half-life of GLP-1. Interestingly, the long-lasting beneficial effects of short-term GLP-1 infusion have been shown to persist for weeks even when the circulating levels of GLP-1 return back to normal levels.⁴⁹

The central finding of the present study is that highly selective GLP-1R antagonist Ex(9-39) administered before RIPre or RIPer blocks cardioprotection induced by both Rlc stimuli. GLP-1R blockade also prevented the stimulatory effect of RIPre on AKT phosphorylation. It appears that different animal species recruit distinct cardioprotective signalling pathways. In rodents, RISK pathway (AKT) activation is essential to establish cardioprotection,⁵⁰ but SAFE pathway (STAT3) also plays a role.⁵¹ In mice and rats, robust activation of RISK and SAFE pathways is observed in isolated hearts and *in vivo* preparations following application of various conditioning stimuli (RIPre and remote postconditioning) as well as pharmacologically.^{11,50,52-56} Importantly, there is also evidence that both Rlc cardioprotection⁵² and cardioprotection induced by activation of GLP-

1R⁵⁷ are abolished in conditions of AKT blockade. In rodents, inhibition of either RISK or SAFE pathway blocks cardioprotection^{11,52,54,56} suggesting that the elements of these two protective pathways may interact. In pigs and humans, cardioprotection appears to be predominantly associated with activation of SAFE pathway.^{58,59} The data obtained in this study suggest that (at least in rats) GLP-1R-mediated signalling is essential for Rlc cardioprotection by being responsible for triggering activation of the pro-survival RISK pathway and, therefore, GLP-1 is likely to act as the key humoral factor of this phenomenon.

4.4 The significance of cardiac vagal mechanisms in cardioprotection induced by GLP-1R activation

Potent cardioprotective effects of GLP-1R agonists have been demonstrated previously.³⁰ However, the underlying mechanisms of GLP-1R-mediated cardioprotection remained largely unknown. Data showing that only atrial cardiomyocytes express GLP-1R,⁴⁷ together with the evidence that GLP-1R agonists can establish cardioprotection in conditions of selective genetic GLP-1R deletion in ventricular cardiomyocytes,²⁹ highlight major gaps in our understanding of GLP-1-induced cardioprotection. Here we addressed the potential mechanisms using systemic administration of a stable GLP-1R agonist Ex4, which is not readily cleaved by DPP-4. Cardioprotection established by Ex4 was found to be abolished in conditions of systemic muscarinic receptor blockade with atropine and, more specifically, M3 receptor blockade with 4-DAMP, whereas vagotomy had no effect. These data suggest that (most likely) cardiac M3-receptor mediated mechanisms are crucial for cardioprotection induced by Ex4. The hypothesised functions of cardiac M3 receptors include regulation of heart rate and cardiac repolarization, modulation of inotropic effects, regulation of cell-to-cell communication, and protection from ischaemia/reperfusion injury.⁶⁰ We suggest that GLP-1 activates GLP-1R expressed by vagal efferent fibres innervating the ventricles, triggering pre-junctional release of acetylcholine, which protects ventricular cardiomyocytes via activation of M3 muscarinic receptors. Although, testing this hypothesis is beyond the scope of the present study, it is strongly supported by the recent data obtained by Pickard and colleagues showing that in isolated rat hearts, cardioprotection established by plasma dialysate from donor rats receiving Rlc stimulus is abolished by muscarinic receptor blockade.⁴¹

4.5 Translational perspective

Results of several clinical studies demonstrated the efficacy of Rlc in reducing infarct size in patients with AMI^{4,5} as well as improvement of long term prognosis in these patients.⁶ Other clinical reports demonstrated lack of Rlc effect in patients undergoing cardiac surgery.⁶¹ In contrast, clinical studies which tested the efficacy of GLP-1R agonists in establishing cardioprotection demonstrated significant reductions in infarct size, regardless of comorbidities and prescribed medications.^{31,32} Results of the present study demonstrate that Rlc cardioprotection is dependent on the actions of GLP-1, while cardioprotection induced by GLP-1R activation is independent of parasympathetic mechanisms but is mediated via M3 muscarinic receptor activation. These results provide a strong rationale for combination of Rlc and intravenous GLP-1R agonists in patients with AMI.

Supplementary material

Supplementary material is available at *Cardiovascular Research* online.

Conflict of interest: none declared.

Funding

This work was supported by the British Heart Foundation (Ref: RG/14/4/30736), Medical Research Council (MR/N02589X/1) and The Wellcome Trust (Ref: 200893/Z/16/Z). A.V.G. is a Wellcome Trust Senior Research Fellow. S.M. is a Marie Skłodowska-Curie Research Fellow (Ref: 654691).

References

- Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. *Circ Res* 2015;**116**:674–699.
- Heusch G, Bøtker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. *J Am Coll Cardiol* 2015;**65**:177–195.
- Basalay M, Barsukevich V, Mastitskaya S, Mrochek A, Pernow J, Sjöquist PO, Ackland GL, Gourine AV, Gourine A. Remote ischaemic pre- and delayed postconditioning - similar degree of cardioprotection but distinct mechanisms. *Exp Physiol* 2012;**97**:908–917.
- Bøtker HE, Kharbanda R, Schmidt MR, Böttcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rehling M, Sørensen HT, Redington AN, Nielsen TT. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. *Lancet* 2010;**375**:727–734.
- White SK, Frohlich GM, Sado DM, Maestrini V, Fontana M, Treibel TA, Tehrani S, Flett AS, Meier P, Ariti C, Davies JR, Moon JC, Yellon DM, Hausenloy DJ. Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. *JACC Cardiovasc Interv* 2015;**8**:178–188.
- Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhäuser M, Peters J, Jakob H, Heusch G. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. *Lancet* 2013;**382**:597–604.
- Sloth AD, Schmidt MR, Munk K, Kharbanda RK, Redington AN, Schmidt M, Pedersen L, Sørensen HT, Bøtker HE; CONDI Investigators. Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. *Eur Heart J* 2014;**35**:168–175.
- Dickson EW, Reinhardt CP, Renzi FP, Becker RC, Porcaro WA, Heard SO. Ischemic preconditioning may be transferable via whole blood transfusion: preliminary evidence. *J Thromb Thrombolysis* 1999;**8**:123–129.
- Konstantinov IE, Li J, Cheung MM, Shimizu M, Stokoe J, Kharbanda RK, Redington AN. Remote ischemic preconditioning of the recipient reduces myocardial ischemia-reperfusion injury of the denervated donor heart via a Katp channel-dependent mechanism. *Transplantation* 2005;**79**:1691–1695.
- Shimizu M, Tropak M, Diaz RJ, Suto F, Surendra H, Kuzmin E, Li J, Gross G, Wilson GJ, Callahan J, Redington AN. Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection. *Clin Sci (Lond)* 2009;**117**:191–200.
- Skyschally A, Gent S, Amanakis G, Schulte C, Kleinbongard P, Heusch G. Across-species transfer of protection by remote ischemic preconditioning with species-specific myocardial signal transduction by reperfusion injury salvage kinase and survival activating factor enhancement pathways. *Circ Res* 2015;**117**:279–288.
- Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD. Myocardial protection by brief ischemia in noncardiac tissue. *Circulation* 1996;**94**:2193–2200.
- Mastitskaya S, Marina N, Gourine A, Gilbey MP, Spyer KM, Teschemacher AG, Kasparov S, Trapp S, Ackland GL, Gourine AV. Cardioprotection evoked by remote ischaemic preconditioning is critically dependent on the activity of vagal pre-ganglionic neurones. *Cardiovasc Res* 2012;**95**:487–494.
- Donato M, Buchholz B, Rodríguez M, Pérez V, Inserte J, García-Dorado D, Gelpi RJ. Role of the parasympathetic nervous system in cardioprotection by remote hindlimb ischaemic preconditioning. *Exp Physiol* 2013;**98**:425–434.
- Davidson SM, Selvaraj P, He D, Boi-Doku C, Yellon RL, Vicencio JM, Yellon DM. Remote ischaemic preconditioning involves signalling through the SDF-1 α /CXCR4 signalling axis. *Basic Res Cardiol* 2013;**108**:377.
- Rassaf T, Totzeck M, Hendgen-Cotta UB, Shiva S, Heusch G, Kelm M. Circulating nitrite contributes to cardioprotection by remote ischemic preconditioning. *Circ Res* 2014;**114**:1601–1610.
- Cai ZP, Parajuli N, Zheng X, Becker L. Remote ischemic preconditioning confers late protection against myocardial ischemia-reperfusion injury in mice by upregulating interleukin-10. *Basic Res Cardiol* 2012;**107**:277.

18. Li J, Rohailla S, Gelber N, Rutka J, Sabah N, Gladstone RA, Wei C, Hu P, Kharbada RK, Redington AN. MicroRNA-144 is a circulating effector of remote ischemic preconditioning. *Basic Res Cardiol* 2014;**109**:423.
19. Hibert P, Prunier-Mirebeau D, Beseme O, Chwastyniak M, Tamareille S, Lamon D, Furber A, Pinet F, Prunier F. Apolipoprotein a-I is a potential mediator of remote ischemic preconditioning. *PLoS One* 2013;**8**:e77211.
20. Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG Jr. EGLN1 inhibition and rerouting of α -Ketoglutarate suffice for remote ischemic protection. *Cell* 2016;**164**:884–895.
21. Mastitskaya S, Basalay M, Hosford PS, Ramage AG, Gourine A, Gourine AV. Identifying the source of a humoral factor of remote (Pre)conditioning cardioprotection. *PLoS One* 2016;**11**:e0150108.
22. Calvillo L, Vanoli E, Andreoli E, Besana A, Omodeo E, Gnechi M, Zerbi P, Vago G, Busca F, Schwartz PJ. Vagal stimulation, through its nicotinic action, limits infarct size and the inflammatory response to myocardial ischemia and reperfusion. *J Cardiovasc Pharmacol* 2011;**58**:500–507.
23. Uitterdijk A, Yetgin T, te Lintel Hekkert M, Snee P, Krabbendam-Peters I, van Beusekom HM, Fischer TM, Cornelussen RN, Manintveld OC, Merkus D, Duncker DJ. Vagal nerve stimulation started just prior to reperfusion limits infarct size and no-reflow. *Basic Res Cardiol* 2015;**110**:508.
24. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. *Circ Res* 2014;**114**:1788–1803.
25. Drucker DJ. Deciphering metabolic messages from the gut drives therapeutic innovation: the 2014 Banting Lecture. *Diabetes* 2015;**64**:317–326.
26. Holst JJ. The physiology of glucagon-like peptide 1. *Physiol Rev* 2007;**87**:1409–1439.
27. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. *Endocrinology* 1999;**140**:1687–1694.
28. Ban K, Noyan-Ashraf MH, Hoefler J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. *Circulation* 2008;**117**:2340–2350.
29. Ussher JR, Baggio LL, Campbell JE, Mulvihill EE, Kim M, Kabir MG, Cao X, Baranek BM, Stoffers DA, Seeley RJ, Drucker DJ. Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. *Mol Metab* 2014;**3**:507–517.
30. Ravassa S, Zudaire A, Diez J. GLP-1 and cardioprotection: from bench to bedside. *Cardiovasc Res* 2012;**94**:316–323.
31. Lønborg J, Kelbæk H, Vejstrup N, Bøtker HE, Kim WY, Holmvang L, Jørgensen E, Helqvist S, Saunamäki K, Terkelsen CJ, Schoos MM, Køber L, Clemmensen P, Treiman M, Engstrøm T. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. *Circ Cardiovasc Interv* 2012;**5**:288–295.
32. Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, Seon HJ, Kim KS. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. *Arterioscler Thromb Vasc Biol* 2013;**33**:2252–2260.
33. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in Type 2 diabetes. *N Engl J Med* 2016;**375**:311–322.
34. Lang SC, Elsässer A, Scheler C, Vetter S, Tiefenbacher CP, Kübler W, Katus HA, Vogt AM. Myocardial preconditioning and remote renal preconditioning—identifying a protective factor using proteomic methods? *Basic Res Cardiol* 2006;**101**:149–158.
35. Prectl JC, Powley TL. Organization and distribution of the rat subdiaphragmatic vagus and associated paraganglia. *J Comp Neurol* 1985;**235**:182–195.
36. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. *J Biol Chem* 1993;**268**:19650–19655.
37. Thorens B, Porret A, Bühler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. *Diabetes* 1993;**42**:1678–1682.
38. Barragán JM, Eng J, Rodríguez R, Blázquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. *Am J Physiol* 1999;**277**:E784–E791.
39. Bao W, Holt LJ, Prince RD, Jones GX, Aravindhan K, Szapacs M, Barbour AM, Jolivet LJ, Lepore JJ, Willette RN, DeAngelis E, Jucker BM. Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat. *Cardiovasc Diabetol* 2013;**12**:148.
40. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. *Cell Metab* 2016;**24**:15–30.
41. Pickard JM, Davidson SM, Hausenloy DJ, Yellon DM. Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning. *Basic Res Cardiol* 2016;**111**:50.
42. Gourine A, Gourine AV, Mastitskaya S, Ackland G. “Remote preconditioning reflex”: a neural pathway of cardioprotection during myocardial ischaemia and reperfusion induced by remote ischemic preconditioning. *Eur Heart J* 2010;**31**:319.
43. Machhada A, Ang R, Ackland GL, Ninkina N, Buchman VL, Lythgoe MF, Trapp S, Tinker A, Marina N, Gourine AV. Control of ventricular excitability by neurons of the dorsal motor nucleus of the vagus nerve. *Heart Rhythm* 2015;**12**:2285–2293.
44. Machhada A, Marina N, Korsak A, Stuckey DJ, Lythgoe MF, Gourine AV. Origins of the vagal drive controlling left ventricular contractility. *J Physiol* 2016;**594**:4017–4030.
45. Hepponstall M, Ignjatovic V, Binos S, Monagle P, Jones B, Cheung MH, d’Udekem Y, Konstantinov IE. Remote ischemic preconditioning (RIPC) modifies plasma proteome in humans. *PLoS One* 2012;**7**:e48284.
46. Hibert P, Prunier-Mirebeau D, Beseme O, Chwastyniak M, Tamareille S, Pinet F, Prunier F. Modifications in rat plasma proteome after remote ischemic preconditioning (RIPC) stimulus: identification by a SELDI-TOF-MS approach. *PLoS One* 2014;**9**:e85669.
47. Wallner M, Kolesnik E, Ablasser K, Khafaga M, Wakula P, Ljubojevic S, Thon-Gutsch EM, Sourij H, Kapl M, Edmunds NJ, Kuzmiski JB, Griffith DA, Knez I, Pieske B, von Lewinski D. Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. *J Mol Cell Cardiol* 2015;**89**:365–375.
48. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma *in vitro* yields an N-terminally truncated peptide that is a major endogenous metabolite *in vivo*. *Clin Endocrinol Metab* 1995;**80**:952–957.
49. Hui H, Farilla L, Merkel P, Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. *Eur J Endocrinol* 2002;**146**:863–869.
50. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. *Cardiovasc Res* 2004;**61**:448–460.
51. Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. *Antioxid Redox Signal* 2011;**14**:893–907.
52. Tamareille S, Mateus V, Ghaboura N, Jeanneteau J, Croué A, Henrion D, Furber A, Prunier F. RISK and SAFE signaling pathway interactions in remote limb ischemic preconditioning in combination with local ischemic postconditioning. *Basic Res Cardiol* 2011;**106**:1329–1339.
53. Xin P, Zhu W, Li J, Ma S, Wang L, Liu M, Li J, Wei M, Redington AN. Combined local ischemic postconditioning and remote preconditioning recapitulate cardioprotective effects of local ischemic preconditioning. *Am J Physiol Heart Circ Physiol* 2010;**298**:H1819–H1831.
54. Fuglestad BN, Suleman N, Tiron C, Kanhema T, Lacerda L, Andreassen TV, Sack MN, Jonassen AK, Mjos OD, Opie LH, Lecour S. Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion. *Basic Res Cardiol* 2008;**103**:444–453.
55. Lacerda L, Somers S, Opie LH, Lecour S. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. *Cardiovasc Res* 2009;**84**:201–208.
56. Suleman N, Somers S, Smith R, Opie LH, Lecour SC. Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning. *Cardiovasc Res* 2008;**79**:127–133.
57. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. *Diabetes* 2005;**54**:146–151.
58. Heusch G, Musiolik J, Gedik N, Skyschally A. Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. *Circ Res* 2011;**109**:1302–1308.
59. Heusch G, Musiolik J, Kottenberg E, Peters J, Jakob H, Thielmann M. STAT5 activation and cardioprotection by remote ischemic preconditioning in humans: short communication. *Circ Res* 2012;**110**:111–115.
60. Wang H, Lu Y, Wang Z. Function of cardiac M3 receptors. *Auton Autacoid Pharmacol* 2007;**27**:1–11.
61. Heusch G, Gersh BJ. ERICCA and RIPHeart: two nails in the coffin for cardioprotection by remote ischemic conditioning? Probably not! *Eur Heart J* 2016;**37**:200–202.